You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePlasmin
Accession NumberDB05254
TypeSmall Molecule
GroupsInvestigational
DescriptionPlasmin (also known as Fibrinolysin) is a bovine enzyme derived from bovine plasma or extracted from bacterial cultures. It is a globular protein with a molecular weight of ~90,000 daltons. Plasmin consists of two polypeptide chains, one light and one heavy, linked by a disulfide bond. The light chain has a molecular weight of approximately 27,000 Da and contains the active center of plasmin; the heavy chain has a molecular weight of approximately 57,000 Da. Plasmin is used as a local healing ointment when combined together with the enzyme deoxyribonuclease I (extracted from bovine pancreas). Plasmin and deoxyribonuclease both act as lytic enzymes. The combination is available as ointment containing 1 BU (Biological Unit) plasmin and 666 BUs desoxyribonuclease per gram. The ointment is marketed by Pfizer under the brand name Fibrolan in a variety of countries (e.g. Switzerland). It is currently not approved in the USA.
Structure
Thumb
Synonyms
Bovine Fibrinolysin
Bovine Plasmin
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ElaseNot Available
FibrolanNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIINot Available
CAS numberNot Available
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available
Pharmacology
IndicationPlasmin assists with the healing of minor burns, superficial wounds, ulcers, surgical wounds, and superficial hematomas
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionPlasmin attacks and inactivates fibrin molecules occurring in undesirable exudates on the surface of the human body and on human mucosa, e.g., in superficial wounds and burns, while desoxyribonuclease targets and destroys (human) DNA. The combination of the two enzymes has a synergistic effect on necrotic but not on living tissue.
TargetKindPharmacological actionActionsOrganismUniProt ID
Plasminogen activator inhibitor 1ProteinunknownNot AvailableHumanP05121 details
Urokinase-type plasminogen activatorProteinunknownNot AvailableHumanP00749 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

local inactivation

Route of eliminationNot Available
Half lifeAlmost completely inactivated after 24 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbciximabPlasmin may increase the anticoagulant activities of Abciximab.Approved
AcenocoumarolPlasmin may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Plasmin.Approved, Vet Approved
AlprostadilAlprostadil may increase the anticoagulant activities of Plasmin.Approved, Investigational
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Plasmin.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Plasmin.Approved
AncrodPlasmin may increase the anticoagulant activities of Ancrod.Investigational
Antithrombin III humanPlasmin may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanPlasmin may increase the anticoagulant activities of Apixaban.Approved
AprotininThe therapeutic efficacy of Plasmin can be decreased when used in combination with Aprotinin.Approved, Withdrawn
ArdeparinPlasmin may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanPlasmin may increase the anticoagulant activities of Argatroban.Approved, Investigational
AzelastineAzelastine may increase the anticoagulant activities of Plasmin.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Plasmin.Approved, Investigational
BecaplerminPlasmin may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeraprostBeraprost may increase the anticoagulant activities of Plasmin.Investigational
BivalirudinPlasmin may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
ButylphthalideButylphthalide may increase the anticoagulant activities of Plasmin.Investigational
CangrelorCangrelor may increase the anticoagulant activities of Plasmin.Approved
CertoparinPlasmin may increase the anticoagulant activities of Certoparin.Approved
CilostazolCilostazol may increase the anticoagulant activities of Plasmin.Approved
Citric AcidPlasmin may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Plasmin.Approved, Nutraceutical
Dabigatran etexilatePlasmin may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinPlasmin may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidPlasmin may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DefibrotideDefibrotide may increase the anticoagulant activities of Plasmin.Approved, Investigational
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Plasmin.Investigational
DesirudinPlasmin may increase the anticoagulant activities of Desirudin.Approved
DextranPlasmin may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Plasmin may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Plasmin may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Plasmin may increase the anticoagulant activities of Dextran 75.Approved
DicoumarolPlasmin may increase the anticoagulant activities of Dicoumarol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Plasmin.Approved
DipyridamoleDipyridamole may increase the anticoagulant activities of Plasmin.Approved
Edetic AcidPlasmin may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanPlasmin may increase the anticoagulant activities of Edoxaban.Approved
EnoxaparinPlasmin may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineEpinastine may increase the anticoagulant activities of Plasmin.Approved, Investigational
eplivanserineeplivanserine may increase the anticoagulant activities of Plasmin.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Plasmin.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Plasmin.Approved, Investigational
Ethyl biscoumacetatePlasmin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
FluindionePlasmin may increase the anticoagulant activities of Fluindione.Investigational
FondaparinuxPlasmin may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumPlasmin may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
GabexatePlasmin may increase the anticoagulant activities of Gabexate.Investigational
HeparinPlasmin may increase the anticoagulant activities of Heparin.Approved, Investigational
HirulogPlasmin may increase the anticoagulant activities of Hirulog.Experimental
IbudilastIbudilast may increase the anticoagulant activities of Plasmin.Approved, Investigational
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Plasmin.Approved, Nutraceutical
idraparinuxPlasmin may increase the anticoagulant activities of idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Plasmin.Approved, Withdrawn
IloprostIloprost may increase the anticoagulant activities of Plasmin.Approved, Investigational
KetanserinKetanserin may increase the anticoagulant activities of Plasmin.Investigational
LepirudinPlasmin may increase the anticoagulant activities of Lepirudin.Approved
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Plasmin.Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Plasmin.Approved
MilrinoneMilrinone may increase the anticoagulant activities of Plasmin.Approved
NadroparinPlasmin may increase the anticoagulant activities of Nadroparin.Approved
NafamostatPlasmin may increase the anticoagulant activities of Nafamostat.Investigational
NaftopidilNaftopidil may increase the anticoagulant activities of Plasmin.Investigational
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Plasmin.Investigational
NimesulideNimesulide may increase the anticoagulant activities of Plasmin.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Plasmin.Investigational
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Plasmin.Approved
OtamixabanPlasmin may increase the anticoagulant activities of Otamixaban.Investigational
Pentosan PolysulfatePlasmin may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Plasmin.Approved, Investigational
PhenindionePlasmin may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonPlasmin may increase the anticoagulant activities of Phenprocoumon.Approved
PrasugrelPrasugrel may increase the anticoagulant activities of Plasmin.Approved
Protein CPlasmin may increase the anticoagulant activities of Protein C.Approved
Protein S humanPlasmin may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydePlasmin may increase the anticoagulant activities of Protocatechualdehyde.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Plasmin.Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Plasmin.Experimental, Investigational
ReviparinPlasmin may increase the anticoagulant activities of Reviparin.Approved
RidogrelRidogrel may increase the anticoagulant activities of Plasmin.Approved
RivaroxabanPlasmin may increase the anticoagulant activities of Rivaroxaban.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Plasmin.Approved, Vet Approved
SCH-530348SCH-530348 may increase the anticoagulant activities of Plasmin.Investigational
SevofluraneSevoflurane may increase the anticoagulant activities of Plasmin.Approved, Vet Approved
SRT501SRT501 may increase the anticoagulant activities of Plasmin.Investigational
SulodexidePlasmin may increase the anticoagulant activities of Sulodexide.Approved, Investigational
TesmilifeneTesmilifene may increase the anticoagulant activities of Plasmin.Investigational
TiclopidineTiclopidine may increase the anticoagulant activities of Plasmin.Approved
TirofibanTirofiban may increase the anticoagulant activities of Plasmin.Approved
TranilastTranilast may increase the anticoagulant activities of Plasmin.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Plasmin.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Plasmin is combined with Treprostinil.Approved, Investigational
TriflusalTriflusal may increase the anticoagulant activities of Plasmin.Approved
VorapaxarVorapaxar may increase the anticoagulant activities of Plasmin.Approved
WarfarinPlasmin may increase the anticoagulant activities of Warfarin.Approved
XimelagatranPlasmin may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Plasmin may increase the anticoagulant activities of Ym150.Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Birk Y, Khalef S, Jibson MD: Purification and properties of protease F, a bacterial enzyme with chymotrypsin and elastase specificities. Arch Biochem Biophys. 1983 Sep;225(2):451-7. [PubMed:6226244 ]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET featuresNot Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US2624691 No1953-01-061980-01-06Us
US3136703 No1964-06-091981-06-09Us
US3234106 No1966-02-081983-02-08Us
Properties
StateLiquid
Experimental PropertiesNot Available
Predicted PropertiesNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Taxonomy
ClassificationNot classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serine-type endopeptidase inhibitor activity
Specific Function:
Serine protease inhibitor. This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, protein C and matriptase-3/TMPRSS7. Its rapid interaction with PLAT may function as a major control point in the regulation of fibrinolysis.
Gene Name:
SERPINE1
Uniprot ID:
P05121
Molecular Weight:
45059.695 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serine-type endopeptidase activity
Specific Function:
Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.
Gene Name:
PLAU
Uniprot ID:
P00749
Molecular Weight:
48507.09 Da
Comments
comments powered by Disqus
Drug created on November 18, 2007 11:09 / Updated on August 17, 2016 12:24